Ascendis Pharma A/S reports results for the quarter ended December 31 - Earnings Summary

Ascendis Pharma A/S

13/02/2025 02:55

* Ascendis Pharma A/S  ASND.OQ  reported a quarterly
adjusted loss
of 64 cents​​ per share for the quarter ended December 31,
higher than the same quarter last year, when the company
reported EPS of €-1.54.  The mean expectation of
fourteen analysts for the quarter was for a loss of 96 cents per
share. Wall Street expected results to range from €-1.78 to 23
cents per share.
    * Revenue rose 26.3% to €173.92 million from a year ago;
analysts
expected €119.71 million. 
    * Ascendis Pharma A/S's reported EPS for the quarter was a
loss
of 64 cents​.
    * The company reported a quarterly loss of €38.47 million.
    * Ascendis Pharma A/S shares had fallen by 13.2% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 33.9%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Ascendis Pharma
A/S is $196.00 
This summary was machine generated from LSEG data February 13 at
02:55 a.m. UTC. ​All figures in euros unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -0.96          -0.64          Beat
 Sep. 30 2024      -1.74          -1.72          Beat
 Jun. 30 2024      -1.38          -1.91          Missed
 Mar. 31 2024      -1.50          -2.30          Missed